Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$18.55

0.85 (4.80%)

09:05
11/28/16
11/28
09:05
11/28/16
09:05

Global Blood Therapeutics initiates Phase 2a trial of GBT440

Global Blood Therapeutics announced enrollment of the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety and efficacy of GBT440 for the treatment of hypoxemia in patients with idiopathic pulmonary fibrosis who are on supplemental oxygen at rest.

  • 03

    Dec

  • 19

    Dec

GBT Global Blood Therapeutics
$18.55

0.85 (4.80%)

09/30/16
WELS
09/30/16
INITIATION
WELS
Outperform
Global Blood Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Global Blood Therapeutics with an Outperform rating and $75-$81 price target range. The analyst has a positive outlook for the company's hemoglobin modifier GBT440 in Sickle Cell Disease. He views GBT440 as a best-in-class hemoglobin modifier and estimates peak sales at $2.7B.
10/25/16
COWN
10/25/16
NO CHANGE
Target $83
COWN
Outperform
Global Blood Therapeutics price target raised to $83 from $80 at Cowen
Cowen analyst Ritu Baral raised his price target on Global Blood Therapeutics to $83 from $80 after the company reached a deal with the FDA regarding the design of its pivotal trial for GBT440 for sickle cell. Baral reiterated his Outperform rating on Global Therapeutics shares.
11/01/16
ROTH
11/01/16
INITIATION
Target $47
ROTH
Buy
Global Blood Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach started Global Blood Therapeutics with a Buy rating and $47 price target, saying it represents an attractive investment opportunity as he believes its lead product, GBT440, has the potential to improve the standard of care for patients who suffer from Sickle Cell Anemia.
11/04/16
ROTH
11/04/16
NO CHANGE
Target $47
ROTH
Buy
Global Blood weakness on ASH abstracts unjustified, says Roth Capital
Roth Capital analyst Mark Breidenbach believes Global Blood Therapeutics' GBT440 has the potential to markedly improve the standard of care for patients who suffer from sickle cell anemia. With an upcoming readout expected at ASH that could significantly de-risk the company's planned pivotal trial, the analyst believes Global Blood Therapeutics represents an "excellent investment opportunity." Further, Breidenbach notes that the shares' weakness following the publication of abstracts for the upcoming 2016 ASH meeting seems to be unjustified. He says Global Blood Therapeutics remains a Focus Pick, and reiterates a Buy rating and $47 price target on the shares.

TODAY'S FREE FLY STORIES

AZZ

AZZ Inc.

$59.10

2.52 (4.45%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
AZZ Inc. awarded contract from Beijing Sino-American Yuli Power Technology »

AZZ Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$25.33

0.71 (2.88%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Earnings
Fifth Third reports Q1 EPS 38c, consensus 37c »

Reports Q1 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MDT

Medtronic

$80.65

0.17 (0.21%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
Medtronic says DCB demonstrates consistent results »

Medtronic reinforced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 06

    Jun

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Hot Stocks
PulteGroup reports backlog of 9,323 homes at Q1-end »

For the quarter, net new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

GPK

Graphic Packaging

$13.58

0.04 (0.30%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Earnings
Graphic Packaging reports Q1 EPS 14c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    May

EPZM

Epizyme

$14.90

0.35 (2.41%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
FDA grants Fast Track designation to Epizyme's tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$44.29

0.69 (1.58%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Earnings
CIT Group reports Q1 EPS ex-items 80c, consensus 59c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
PulteGroup reports Q1 value of net new orders up 16% to $2.4B »

Net New Orders Up 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

BA

Boeing

$182.06

1.68 (0.93%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Periodicals
Boeing nears decision on 737-10 jet launch, Reuters reports »

Boeing (BA) is close to a…

BA

Boeing

$182.06

1.68 (0.93%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Earnings
PulteGroup reports Q1 EPS 28c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Hot Stocks
Supervalu reports Q4 retail identical store sales down 5.8% »

Total net sales within…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Nielsen sees FY17 GAAP EPS $1.40-$1.46 , consensus $2.68 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

FBC

Flagstar Bancorp

$28.69

0.31 (1.09%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Flagstar Bancorp reports Q1 EPS 46c, consensus 38c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 23

    May

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Nielsen reports Q1 EPS 20c, consensus 48c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Supervalu reports Q4 adjusted EPS 13c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHI

Baker Hughes

$58.65

0.97 (1.68%)

06:30
04/25/17
04/25
06:30
04/25/17
06:30
Earnings
Baker Hughes reports Q1 adjusted EPS (4c), consensus (21c) »

Reports Q1 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:29
04/25/17
04/25
06:29
04/25/17
06:29
Hot Stocks
Eli Lilly backs FY17 EPS view of $4.05-$4.15, consensus $4.11 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WHR

Whirlpool

$174.80

3.29 (1.92%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Hot Stocks
Whirlpool sees about $300M of raw material inflation in 2017 »

Says had sort-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Earnings
Eli Lilly reports Q1 EPS 98c, consensus 96c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WEGRY

Weir Group

$12.91

0.71 (5.82%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Upgrade
Weir Group rating change  »

Weir Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$79.37

0.72 (0.92%)

06:26
04/25/17
04/25
06:26
04/25/17
06:26
Hot Stocks
Breaking Hot Stocks news story on DuPont »

DuPont up 2.1% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

, FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

06:25
04/25/17
04/25
06:25
04/25/17
06:25
Periodicals
Former presenter names Fox News executives in new lawsuit, FT says »

Andrea Tantaros, a former…

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

CTSH

Cognizant

$58.89

1.04 (1.80%)

06:24
04/25/17
04/25
06:24
04/25/17
06:24
Recommendations
Cognizant analyst commentary  »

Cognizant fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

  • 09

    May

  • 12

    May

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

ST

Sensata

$42.76

1.71 (4.17%)

06:16
04/25/17
04/25
06:16
04/25/17
06:16
Earnings
Sensata sees FY17 adjusted EPS $3.08-$3.20, consensus $3.14 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.